+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Continuous Glucose Monitoring Systems Market by Component, Demography, End-user: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 284 Pages
  • February 2023
  • Region: Global
  • Allied Market Research
  • ID: 5118783
UP TO OFF until Nov 15th 2024
The continuous glucose monitoring systems market was valued at $6,626.6 million in 2021, and is estimated to reach $31,708.2 million by 2031, growing at a CAGR of 17.0% from 2022 to 2031.The continuous glucose monitoring systems (CGMs) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. CGMs are mainly used by patients suffering from hypo and hyperglycemic conditions. There are several different types of CGM systems available in the market, each with its own set of features and benefits such as interstitial fluid CGMs, blood glucose CGMs, and hybrid closed loop CGMs. These systems offer various advantages such as improved glucose control, reduced need for fingerstick testing, increased awareness of glucose patterns, and improved quality of life.

The continuous glucose monitoring systems market growth is driven by increase in number of patients suffering from diabetes; rise in technological advancements such as the development of miniaturized and wearable devices that can provide real-time glucose readings; and increase in patient awareness about be benefits of CGMs. The rise in prevalence of diabetes propels high adoption of CGMs for monitoring glucose levels. The sensor is implanted in the layer of skin which measure glucose levels in the interstitial fluid and a receiver displays the readings. For instance, according to International Diabetes Federation (IDF), about 537 million adults are living with diabetes in 2021, across the globe. In addition, as per the same source, over 3 in 4 adults with diabetes live in low and middle-income countries such as India and China. Thus, rise in the prevalence of diabetes has resulted in increased demand for CGMs, which, in turn, contribute to the market growth.

Furthermore, increase in government initiatives and reimbursement policies are the key factors that boost the market growth. For instance, the Australian Government has implemented the continuous glucose monitoring (CGM) Initiative as part of the National Diabetes Services Scheme (NDSS) to provide access to fully subsidized Dexcom CGMs for eligible people with Type 1 diabetes. This initiative is designed to improve the quality of life for people with Type 1 diabetes and reduce the risk of complications associated with the condition. By providing access to fully subsidized CGMs, the government is helping to make these devices more widely available and accessible to people with Type 1 diabetes. Furthermore, rise in funding activities to conduct the clinical evaluations of CGMs, further contribute towards the market growth. For instance, European Commission's Horizon 2020 program provided funding of $2.85 million for the continued development of non-invasive touch glucose monitoring technology, GlucoBeam. Therefore, such initiatives taken by government supports the company to continue the research and testing of novel CGMs, which, in turn, boost the market growth.

However, the high cost of CGM systems, and complexity of devices limit the adoption of CGMs, which, in turn, restrains the market growth.

On the other hand, increased demand of medical devices in the developed countries such as the U.S., Canada, and rest of world and growth potential in emerging markets expected to create immense opportunities for CGMs during the forecast period.

The continuous glucose monitoring systems market is segmented on the basis of component, demography, end user, and region. On the basis of component, the market is classified into sensors and transmitters & receivers. On the basis of demography, the market is segmented into child population (≤14 years) and adult population (>14 years). On the basis of end user, the market is classified into hospitals & clinics, home healthcare, and others. The others include ambulatory settings and diagnostic center.

Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, New Zealand, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, Venezuela, Argentina, and rest of LAMEA).

Major key players that operate in the global continuous glucose monitoring systems market are A. Menarini, Diagnostics S.r.l, Abbott Laboratories, DexCom, Inc., F. Hoffman-La Roche Ltd, GlySens Incorporated, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Senseonics, and Ypsomed AG.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous glucose monitoring systems market analysis from 2021 to 2031 to identify the prevailing continuous glucose monitoring systems market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the continuous glucose monitoring systems market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global continuous glucose monitoring systems market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Demography

  • Child Population
  • Adult Population

By End User

  • Home healthcare
  • Others
  • Hospital and Clinics

By Component

  • Transmitters and Receivers
  • Sensors

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Spain
  • Netherlands
  • Norway
  • Sweden
  • Denmark
  • Finland
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • New Zealand
  • Philippines
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Venezuela
  • Argentina
  • Rest of LAMEA

Key Market Players

  • Medtronic plc
  • DexCom, Inc.
  • Johnson & Johnson
  • F. Hoffman-La Roche Ltd
  • GlySens Incorporated
  • Novo Nordisk A/S
  • Abbott Laboratories
  • Senseonics
  • A. Menarini Diagnostics S.r.l
  • Ypsomed AG

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in number of people suffering from diabetes
3.4.1.2. Benefits of CGMs over conventional glucose monitoring devices
3.4.1.3. High adoption rate of CGMs in home healthcare and ICUs
3.4.2. Restraints
3.4.2.1. Adverse effects associated with CGMs
3.4.2.2. High cost of CGMs
3.4.3. Opportunities
3.4.3.1. High undiagnosed patient population
3.4.3.2. Technological advancement in CGMs
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT
4.1. Overview
4.1.1. Market size and forecast
4.2. Sensors
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Transmitters and Receivers
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY
5.1. Overview
5.1.1. Market size and forecast
5.2. Child Population
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Adult Population
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Home healthcare
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Component
7.2.3. Market size and forecast, by Demography
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Component
7.2.5.1.3. Market size and forecast, by Demography
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Component
7.2.5.2.3. Market size and forecast, by Demography
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Component
7.2.5.3.3. Market size and forecast, by Demography
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Component
7.3.3. Market size and forecast, by Demography
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Component
7.3.5.1.3. Market size and forecast, by Demography
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Component
7.3.5.2.3. Market size and forecast, by Demography
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Component
7.3.5.3.3. Market size and forecast, by Demography
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Component
7.3.5.4.3. Market size and forecast, by Demography
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Russia
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Component
7.3.5.5.3. Market size and forecast, by Demography
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Spain
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Component
7.3.5.6.3. Market size and forecast, by Demography
7.3.5.6.4. Market size and forecast, by End User
7.3.5.7. Netherlands
7.3.5.7.1. Key market trends, growth factors and opportunities
7.3.5.7.2. Market size and forecast, by Component
7.3.5.7.3. Market size and forecast, by Demography
7.3.5.7.4. Market size and forecast, by End User
7.3.5.8. Norway
7.3.5.8.1. Key market trends, growth factors and opportunities
7.3.5.8.2. Market size and forecast, by Component
7.3.5.8.3. Market size and forecast, by Demography
7.3.5.8.4. Market size and forecast, by End User
7.3.5.9. Sweden
7.3.5.9.1. Key market trends, growth factors and opportunities
7.3.5.9.2. Market size and forecast, by Component
7.3.5.9.3. Market size and forecast, by Demography
7.3.5.9.4. Market size and forecast, by End User
7.3.5.10. Denmark
7.3.5.10.1. Key market trends, growth factors and opportunities
7.3.5.10.2. Market size and forecast, by Component
7.3.5.10.3. Market size and forecast, by Demography
7.3.5.10.4. Market size and forecast, by End User
7.3.5.11. Finland
7.3.5.11.1. Key market trends, growth factors and opportunities
7.3.5.11.2. Market size and forecast, by Component
7.3.5.11.3. Market size and forecast, by Demography
7.3.5.11.4. Market size and forecast, by End User
7.3.5.12. Rest of Europe
7.3.5.12.1. Key market trends, growth factors and opportunities
7.3.5.12.2. Market size and forecast, by Component
7.3.5.12.3. Market size and forecast, by Demography
7.3.5.12.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Component
7.4.3. Market size and forecast, by Demography
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Component
7.4.5.1.3. Market size and forecast, by Demography
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Component
7.4.5.2.3. Market size and forecast, by Demography
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Component
7.4.5.3.3. Market size and forecast, by Demography
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Component
7.4.5.4.3. Market size and forecast, by Demography
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Component
7.4.5.5.3. Market size and forecast, by Demography
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. New Zealand
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Component
7.4.5.6.3. Market size and forecast, by Demography
7.4.5.6.4. Market size and forecast, by End User
7.4.5.7. Philippines
7.4.5.7.1. Key market trends, growth factors and opportunities
7.4.5.7.2. Market size and forecast, by Component
7.4.5.7.3. Market size and forecast, by Demography
7.4.5.7.4. Market size and forecast, by End User
7.4.5.8. Rest of Asia-Pacific
7.4.5.8.1. Key market trends, growth factors and opportunities
7.4.5.8.2. Market size and forecast, by Component
7.4.5.8.3. Market size and forecast, by Demography
7.4.5.8.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Component
7.5.3. Market size and forecast, by Demography
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Component
7.5.5.1.3. Market size and forecast, by Demography
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Component
7.5.5.2.3. Market size and forecast, by Demography
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Component
7.5.5.3.3. Market size and forecast, by Demography
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Venezuela
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Component
7.5.5.4.3. Market size and forecast, by Demography
7.5.5.4.4. Market size and forecast, by End User
7.5.5.5. Argentina
7.5.5.5.1. Key market trends, growth factors and opportunities
7.5.5.5.2. Market size and forecast, by Component
7.5.5.5.3. Market size and forecast, by Demography
7.5.5.5.4. Market size and forecast, by End User
7.5.5.6. Rest of LAMEA
7.5.5.6.1. Key market trends, growth factors and opportunities
7.5.5.6.2. Market size and forecast, by Component
7.5.5.6.3. Market size and forecast, by Demography
7.5.5.6.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Medtronic plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Abbott Laboratories
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. DexCom, Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Senseonics
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Key strategic moves and developments
9.5. Johnson & Johnson
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. A. Menarini Diagnostics S.r.l
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Novo Nordisk A/S
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. GlySens Incorporated
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Ypsomed AG
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. F. Hoffman-La Roche Ltd
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
TABLE 01. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 02. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS , BY REGION, 2021-2031 ($MILLION)
TABLE 03. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS AND RECEIVERS , BY REGION, 2021-2031 ($MILLION)
TABLE 04. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 05. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION, BY REGION, 2021-2031 ($MILLION)
TABLE 06. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION, BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 08. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 09. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 12. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 13. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 17. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 18. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 19. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 20. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 21. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 22. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 23. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 24. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 25. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 26. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 27. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 28. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 30. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 31. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 32. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 33. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 34. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 35. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 36. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 37. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 38. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 39. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 40. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 41. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 42. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 43. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 44. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 45. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 46. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 48. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 49. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 50. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 51. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 52. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 53. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 54. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 55. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 57. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 58. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 60. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 61. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 70. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 71. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 73. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 74. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 75. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 76. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 77. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 84. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 85. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 86. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 87. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 88. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 89. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 94. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 95. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 96. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 97. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 98. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 99. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 101. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 102. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 104. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 105. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 106. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 107. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 108. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 109. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 110. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 111. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 112. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
TABLE 113. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
TABLE 114. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 115. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 116. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 117. MEDTRONIC PLC: PRODUCT SEGMENTS
TABLE 118. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 119. MEDTRONIC PLC: KEY STRATERGIES
TABLE 120. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 121. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 122. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 123. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 124. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 125. DEXCOM, INC.: KEY EXECUTIVES
TABLE 126. DEXCOM, INC.: COMPANY SNAPSHOT
TABLE 127. DEXCOM, INC.: PRODUCT SEGMENTS
TABLE 128. DEXCOM, INC.: PRODUCT PORTFOLIO
TABLE 129. DEXCOM, INC.: KEY STRATERGIES
TABLE 130. SENSEONICS: KEY EXECUTIVES
TABLE 131. SENSEONICS: COMPANY SNAPSHOT
TABLE 132. SENSEONICS: PRODUCT SEGMENTS
TABLE 133. SENSEONICS: PRODUCT PORTFOLIO
TABLE 134. SENSEONICS: KEY STRATERGIES
TABLE 135. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 136. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 137. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 138. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 139. A. MENARINI DIAGNOSTICS S. R. L: KEY EXECUTIVES
TABLE 140. A. MENARINI DIAGNOSTICS S. R. L: COMPANY SNAPSHOT
TABLE 141. A. MENARINI DIAGNOSTICS S. R. L: PRODUCT SEGMENTS
TABLE 142. A. MENARINI DIAGNOSTICS S. R. L: PRODUCT PORTFOLIO
TABLE 143. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 144. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 145. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 146. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 147. GLYSENS INCORPORATED: KEY EXECUTIVES
TABLE 148. GLYSENS INCORPORATED: COMPANY SNAPSHOT
TABLE 149. GLYSENS INCORPORATED: PRODUCT SEGMENTS
TABLE 150. GLYSENS INCORPORATED: PRODUCT PORTFOLIO
TABLE 151. YPSOMED AG: KEY EXECUTIVES
TABLE 152. YPSOMED AG: COMPANY SNAPSHOT
TABLE 153. YPSOMED AG: PRODUCT SEGMENTS
TABLE 154. YPSOMED AG: PRODUCT PORTFOLIO
TABLE 155. F. HOFFMAN-LA ROCHE LTD: KEY EXECUTIVES
TABLE 156. F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 157. F. HOFFMAN-LA ROCHE LTD: PRODUCT SEGMENTS
TABLE 158. F. HOFFMAN-LA ROCHE LTD: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
FIGURE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS , BY COUNTRY 2021-2031 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS AND RECEIVERS , BY COUNTRY 2021-2031 (%)
FIGURE 13. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION, BY COUNTRY 2021-2031 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION, BY COUNTRY 2021-2031 (%)
FIGURE 16. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY 2021-2031 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY COUNTRY 2021-2031 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR OTHERS, BY COUNTRY 2021-2031 (%)
FIGURE 20. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY REGION, 2021
FIGURE 21. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 22. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 23. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 24. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 25. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 26. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 27. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 28. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 29. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 30. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 31. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 32. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 33. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 34. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 35. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 36. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 37. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 38. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 39. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 40. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 41. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 42. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 44. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 45. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 46. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 47. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 48. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 49. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 54. COMPETITIVE DASHBOARD
FIGURE 55. COMPETITIVE HEATMAP: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
FIGURE 56. TOP PLAYER POSITIONING, 2021
FIGURE 57. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 63. DEXCOM, INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 64. DEXCOM, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 65. JOHNSON & JOHNSON: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 67. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 68. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. YPSOMED AG: NET SALES, 2019-2021 ($MILLION)
FIGURE 72. YPSOMED AG: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 73. YPSOMED AG: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 74. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 76. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)

Executive Summary

According to the report titled, “Continuous Glucose Monitoring Systems Market," the continuous glucose monitoring systems market was valued at $6,626.6 million in 2021, and is estimated to reach $31,708.2 million by 2031, growing at a CAGR of 17.0% from 2022 to 2031. Continuous Glucose Monitoring Systems (CGMs) are medical devices used to monitor a person's blood glucose levels continuously throughout the day. CGMs are small, wearable devices that use a small sensor inserted under the skin to measure glucose levels in the interstitial fluid. The sensor is usually placed in the upper arm or abdomen and is kept in place for up to two weeks. CGMs are designed to help people with diabetes better manage their condition by providing information on their current glucose levels and alerting them when their levels are too high or too low.

Key factors driving the growth of the continuous glucose monitoring systems market include increase in the demand for early diagnosis, rise in the prevalence of diabetics, and advancement in R & D activities in medical device industry. Increase in number of geriatric population, who are more vulnerable to diabetics is anticipated to drive the application of continuous glucose monitoring systems and boosts the market growth. For instance, according to International Diabetes Federation (IDF), in 2022, the number of diabetic population is expected to reach 643 million by 2030 and 783 million by 2045. In addition, as per the same source, over 3 in 4 adults with diabetes live in low and middle-income countries and Western Pacific had highest diabetic population of 206 million globally in 2021, making diabetes the most common disease across the globe. Furthermore, it offers real-time monitoring of glucose levels, provides historical glucose data and trends. It is also less painful, and timesaving as compared with conventional glucose monitoring devices. In addition, the data obtained by CGMs and trend analysis are highly accurate and reliable as compared to other SMBG devices. Thus, advanced CGMs are more discreet than conventional glucose monitoring systems, which is beneficial for people who need to monitor their glucose levels throughout the day and night. These benefits have fueled their adoption among end users, i.e., hospitals and home healthcare settings, which in turn boosts market growth.

The market also offers growth opportunities to the key players in the market. Increase in number of key players to manufacture Continuous glucose monitoring systems provide lucrative opportunities for growth and expansion of the market. Some of the major key players offering ccontinous glucose monitoring system are Dexcom G6 (Dexcom), next-generation Eversense E3 CGM System (Senseonics Holdings, Inc)., and Guardian™ Connect continuous glucose monitoring (CGM) system (Medtronic). In addition, increase in the number of products, and rise in number of key players are attributed to drive the growth of market. For instance, in October 2022, Dexcom, a leading medical technology company, announced the availability of Dexcom G7 Continuous Glucose Monitoring (CGM), in 7 countries which also include Australia.

The Continuous glucose monitoring systems Market is segmented into component, demography, end user and region. On the basis of component, the market is categorized into sensors and transmitters & receivers. On the basis of demography, the market is segmented into child population (≤14 years) and adult population (>14 years). On the basis of end user, the market is classified into hospitals & clinics, home healthcare, and others. The others include ambulatory settings and diagnostic center.

Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, New Zealand, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, Venezuela, Argentina, and rest of LAMEA).

The key players profiled in the study include A. Menarini, Diagnostics S.r.l, Abbott Laboratories, DexCom, Inc., F. Hoffman-La Roche Ltd, GlySens Incorporated, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Senseonics, and Ypsomed AG. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product approval and agreement to remain competitive and gain advantage over the competitors in the market. In addition, in November 2022, Senseonics Holdings, Inc., one of the leading medical technology companies, announced the collaboration with Nurse Practitioner Group (NPG). The collaboration aims to expand patient access by providing at-home and in-home insertion option Eversense E3 Continuous Glucose Monitoring System (CGM). They also aim to expand the initiative to other key markets across the U.S, in future.

Key Market Insights

  • By component, the sensors segment was the highest revenue contributor to the market and is estimated to reach $19,196.6 million by 2031, with a CAGR of 17.2%.
  • Based on demography, the adult population segment was the highest revenue contributor to the market with a CAGR of 17.1% during the forecast period.
  • Based on end user, the hospital and clinics segment was the highest revenue contributor to the market with a CAGR of 17.4% during the forecast period.
  • Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 17.9% during the forecast period

Companies Mentioned

  • Medtronic plc
  • DexCom, Inc.
  • Johnson & Johnson
  • F. Hoffman-La Roche Ltd
  • GlySens Incorporated
  • Novo Nordisk A/S
  • Abbott Laboratories
  • Senseonics
  • A. Menarini Diagnostics S.r.l
  • Ypsomed AG

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information